CN108403857A - A kind of pharmaceutical composition and its preparation method and application for preventing and/or treating coronary heart disease - Google Patents
A kind of pharmaceutical composition and its preparation method and application for preventing and/or treating coronary heart disease Download PDFInfo
- Publication number
- CN108403857A CN108403857A CN201810550888.4A CN201810550888A CN108403857A CN 108403857 A CN108403857 A CN 108403857A CN 201810550888 A CN201810550888 A CN 201810550888A CN 108403857 A CN108403857 A CN 108403857A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- preparation
- pharmaceutical composition
- heart disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 35
- 229940079593 drug Drugs 0.000 claims abstract description 24
- 238000011282 treatment Methods 0.000 claims abstract description 15
- 241000208340 Araliaceae Species 0.000 claims abstract description 11
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 11
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 11
- 239000009636 Huang Qi Substances 0.000 claims abstract description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 11
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 11
- 235000008434 ginseng Nutrition 0.000 claims abstract description 11
- 241000921453 Rhodobryum Species 0.000 claims abstract description 9
- 241000220317 Rosa Species 0.000 claims abstract description 9
- 239000008280 blood Substances 0.000 claims abstract description 8
- 210000004369 blood Anatomy 0.000 claims abstract description 8
- 230000007812 deficiency Effects 0.000 claims abstract description 8
- 206010033557 Palpitations Diseases 0.000 claims abstract description 7
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 208000031225 myocardial ischemia Diseases 0.000 claims abstract description 5
- 206010019233 Headaches Diseases 0.000 claims abstract description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract description 4
- 231100000869 headache Toxicity 0.000 claims abstract description 4
- 206010022437 insomnia Diseases 0.000 claims abstract description 4
- 244000269722 Thea sinensis Species 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 235000009569 green tea Nutrition 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 235000013616 tea Nutrition 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 206010011703 Cyanosis Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 244000025254 Cannabis sativa Species 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000282 nail Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241001504282 Bryaceae Species 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000014659 low sodium diet Nutrition 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical class [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/10—Bryophyta (mosses)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides a kind of pharmaceutical compositions and its preparation method and application for preventing and/or treating coronary heart disease, it is the preparation that the raw material matched containing following weight is prepared：5~50 parts of Radix Astragali, 5~10 parts of Radix Angelicae Sinensis, 6~10 parts of Radix Glycyrrhizae, 5~10 parts of ganoderma lucidum, 10~20 parts of tealeaves, 10~15 parts of Herba Epimedii, 10~20 parts of Radix Salviae Miltiorrhizae, 5~10 parts of rose rhodobryum herb, 5~10 parts of ginseng, 0.1~1 part of radix aconiti agrestis.The results show, compared with the drug of existing treatment coronary heart disease, the composition of the present invention is more safe and effective, can be applied to the diseases such as coronary heart disease, myocardial ischemia, angina pectoris, treatment deficiency of vital energy weak, headache due to deficiency of blood, palpitation and insomnia, the obstruction of qi in the chest, has a vast market application prospect.
Description
Technical field
The present invention relates to a kind of pharmaceutical compositions and its preparation method and application for preventing and/or treating coronary heart disease.
Background technology
Coronary atherosclerotic heart disease is that coronary artery occurs atherosclerotic lesion and causes blood vessel
Chamber stenosis or occlusion causes heart disease, commonly referred to as " coronary heart disease " caused by myocardial ischemia, anoxic or necrosis.It is mainly in
It is often visible in daily life after 40 years old.There is anterior pectorial region and feels oppressed pain suddenly in clinical manifestation, shortness of breath, sweat all over,
Pale complexion, patient are forced to stop action, and less serious case gradually restores normal, severe after voluntarily capable of alleviating and rest in several minutes
Patient will likely generate serious consequence, and before about 20 years, coronary heart disease comes the cause of death in the U.S. and many developed countries
First.
However, since the 1960s, there is coronary heart disease death rate downward trend in the U.S..Have benefited from the 60-80 ages
The effort for the reduction coronary risk factor that the U.S. is carried out mainly controls risk factor and improves the treatment of myocardial infarction.
Treatment for coronary heart disease includes：1. living habit changes：Smoking cessation limit wine, low-fat low-salt diet, appropriate physical training, control volume
Again etc.；2. drug therapy：Antithrombotic (antiplatelet, anti-freezing) mitigates myocardium keto consumption (beta-blocker), allevating angina pectoris (nitre
Esters of gallic acid), adjust fat to stablize patch (Statins fat regulation medicine)；3. revascularization is treated：Including interventional treatment, (intravascular balloon is expanded
Plasty and Stent) and surgery Coronary Artery Bypass Grafting.Drug therapy is the basis of all treatments.It intervenes and outer
Also long-term standard medication therapy is adhered to after surgical treatment.For same patient, when being in some stage of disease
It can ideally be controlled with drug, and be applied alone medication effect often bad at another stage, need to control drug and intervention
It treats or surgical operation shares.And these Western medicine, which are used for a long time, not only can generate body side effect, also will produce drug resistance.Usually
In the case of, long-term treatment safety, few side effects are carried out using Chinese medicine, liver kidney are stimulated small and not damaged to gastrointestinal tract.
Patent CN 1824008A provide a kind of anti senile dementia drug, Its Preparation Method And Use.The invention Chinese medicine
Prescription and compatibility：110~126 parts of Radix Astragali, 96~112 parts of Radix Codonopsis, 76~86 parts of Radix Salviae Miltiorrhizae, 76~88 parts of pueraria lobata, Herba Epimedii 75~
86 parts, 72~82 parts of hawthorn, 56~66 parts of glutinous rehmannia, 58~68 parts of Radix Angelicae Sinensis, 57~63 parts of the coptis, 53~68 parts of corydalis tuber, ganoderma lucidum
55~68 parts, 22~28 parts of ginseng, 23~27 parts of Radix Glycyrrhizae, by boiling effective component extracting, be prepared as capsule, can pay lower solid
Sheet, qi and activate blood circulation, the analgesic of row arteries and veins, and the symptoms such as coronary heart diseases and angina pectoris can be obviously improved.But it is more multiple that it still has prescription
Miscellaneous, the problems such as preparation process is cumbersome.
Therefore, it is badly in need of a kind of drug of simple and safe, without side-effects treatment coronary heart disease now.
Invention content
In order to solve the above technical problem, the present invention provides a kind of medicine groups for preventing and/or treating coronary heart disease
Object is closed, it is the preparation that the raw material matched containing following weight is prepared：
The present invention is used to prevent and/or treat the pharmaceutical composition of coronary heart disease, it is the raw material matched containing following weight
The preparation that medicine is prepared：40~60 parts of Radix Astragali, 5~15 parts of Radix Angelicae Sinensis, 3~9 parts of Radix Glycyrrhizae, 5~15 parts of ganoderma lucidum, 5~15 parts of tealeaves,
5~15 parts of Herba Epimedii, 40~60 parts of Radix Salviae Miltiorrhizae, 5~15 parts of rose rhodobryum herb, 5~15 parts of ginseng, 1~3 part of radix aconiti agrestis.
Wherein, it is the preparation that the bulk pharmaceutical chemicals matched containing following weight are prepared：It is 50 parts of Radix Astragali, 10 parts of Radix Angelicae Sinensis, sweet
6 parts of grass, 10 parts of ganoderma lucidum, 10 parts of tealeaves, 10 parts of Herba Epimedii, 50 parts of Radix Salviae Miltiorrhizae, 10 parts of rose rhodobryum herb, 10 parts of ginseng, 2 parts of radix aconiti agrestis.
Wherein, the tealeaves is green tea.
Wherein, it is active constituent that it, which is by the medicinal powder of bulk pharmaceutical chemicals, the water of bulk pharmaceutical chemicals or extractive with organic solvent, in addition pharmacy
In the preparation that is prepared of acceptable auxiliary material.
Wherein, the preparation is oral preparation；Preferably, the oral preparation be decoction, powder, capsule, tablet,
Granula.
Wherein, the oral preparation is tea bag.
The present invention also provides the methods of foregoing pharmaceutical composition, it is characterised in that：It includes the following steps：
1) each bulk pharmaceutical chemicals are weighed by weight ratio；
2) medicinal powder, water or extractive with organic solvent of bulk pharmaceutical chemicals are taken, and in pharmacy acceptable auxiliary material or it is complementary at
Divide and is prepared into preparation.
The present invention also provides its take book composition prepare prevent and/or treatment coronary heart disease, myocardial ischemia, angina pectoris,
Treatment deficiency of vital energy weak, headache due to deficiency of blood, palpitation and insomnia and/or the obstruction of qi in the chest drug in purposes.
Wherein, the drug is to alleviate ambition secret anguish, palpitation, lassitude hypodynamia, complexionIt is white and/or cyanosis of the lips and nails
Drug.
Rose rhodobryum herb is the herb of the red great Ye moss of Bryaceae plant.
In Chinese medicine composition of the present invention, heart-yang is helped on monarch drug in a prescription radix aconiti agrestis, eliminating impediment of activating yang, monarch drug in a prescription ginseng, QI invigorating righting enriches blood foster
The heart, compatibility ministerial drug Radix Astragali tonifying Qi lead to numbness with promoting circulation of blood；The pungent row temperature of Radix Angelicae Sinensis leads to eliminating impediment, and row of invigorating blood circulation becomes silted up；Radix Salviae Miltiorrhizae is promoting blood circulation and removing blood stasis, and promoting menstruation stops
Bitterly；Assistant helps Radix Glycyrrhizae Yiqi and vein recovery, the help motive；Herba Epimedii tonifying kidney and strengthening yang；Rose rhodobryum herb, ganoderma lucidum bushing blood, invigorating heart gas, tranquilizing mind；
So that medicine green tea is delayed radix aconiti agrestis high violent pharmacological property, coordinating the drug actions of a prescription prevent it is dry it is strong too.
The results show, compared with the drug of existing treatment coronary heart disease, composition of the invention is more safe and effective, tool
There is wide market application prospect.
Obviously, the above according to the present invention is not being departed from according to the ordinary technical knowledge and customary means of this field
Under the premise of the above-mentioned basic fundamental thought of the present invention, the modification, replacement or change of other diversified forms can also be made.
The specific implementation mode of form by the following examples remakes further specifically the above of the present invention
It is bright.But the range that this should not be interpreted as to the above-mentioned theme of the present invention is only limitted to example below.It is all to be based on the above of the present invention
The technology realized all belongs to the scope of the present invention.
Specific implementation mode
The preparation of embodiment 1, pharmaceutical composition of the present invention
Take 50 grams of Radix Astragali, 10 grams of Radix Angelicae Sinensis, 6 grams of Radix Glycyrrhizae, 10 grams of ganoderma lucidum, 10 grams of green tea, 10 grams of Herba Epimedii, Radix Salviae Miltiorrhizae 50 gram, time
10 grams of heart grass, 10 grams of ginseng, 2 grams of radix aconiti agrestis, crushing is mixed thoroughly, and tea bag is made.
The preparation of embodiment 2, pharmaceutical composition of the present invention
Take 40 grams of Radix Astragali, 15 grams of Radix Angelicae Sinensis, 3 grams of Radix Glycyrrhizae, 15 grams of ganoderma lucidum, 5 grams of green tea, 15 grams of Herba Epimedii, 40 grams of Radix Salviae Miltiorrhizae, Hui Xin
15 grams of grass, 5 grams of ginseng, 3 grams of radix aconiti agrestis, crushing is mixed thoroughly, and water or organic solvent is added to extract, in addition in pharmacy prepared by acceptable auxiliary material
Made of preparation.
The preparation of embodiment 3, pharmaceutical composition of the present invention
Take 60 grams of Radix Astragali, 5 grams of Radix Angelicae Sinensis, 9 grams of Radix Glycyrrhizae, 5 grams of ganoderma lucidum, 15 grams of green tea, 5 grams of Herba Epimedii, 60 grams of Radix Salviae Miltiorrhizae, rose rhodobryum herb
5 grams, 15 grams of ginseng, 1 gram of radix aconiti agrestis, crushing is mixed thoroughly, and water or organic solvent is added to extract, and in pharmacy acceptable auxiliary material prepare and
At preparation.
The experiment of 1 drug therapy coronary heart disease of the present invention of test example
(1) drug
Pharmaceutical composition of the present invention：It is prepared according to the method for embodiment 1
Instructions of taking：Tea bag (every bag of 9g) is prepared according to the method for embodiment 1, and daily one bag, every bag is steeped 5~7 times, often
It is secondary to steep 30min with 300ml boiling water, it is taken instead of daily drinking water.
1 drug of control group：50 grams of Radix Astragali, 10 grams of Radix Angelicae Sinensis, 6 grams of Radix Glycyrrhizae, 10 grams of ganoderma lucidum, 10 grams of green tea, crushing is mixed thoroughly, is made
Tea bag (every bag of 9g).Instructions of taking is the same as pharmaceutical composition of the present invention.
2 drug of control group：10 grams of Herba Epimedii, 50 grams of Radix Salviae Miltiorrhizae, 10 grams of rose rhodobryum herb, 10 grams of ginseng, 2 grams of radix aconiti agrestis, crushing is mixed thoroughly,
Tea bag (every bag of 9g) is made.Instructions of taking is the same as pharmaceutical composition of the present invention.
(2) diagnostic criteria：
Coronary heart disease Chinese medicine category chest-rheumatism, patient symptoms include ambition secret anguish, when as when stop, palpitation, it is dynamic then it is beneficial very, with burnout
Weak, sound is humble, complexionIn vain, cyanosis of the lips and nails, arteries and veins rule is thin slow or ties generation.
(3) standard is treated
It cures：Patient's malaise symptoms complete incidence graph, pulse condition ease up calmly, and the rhythm and pace of moving things is normal；
Effectively：Patient's malaise symptoms are alleviated；
In vain：Patient's malaise symptoms are not improved.
(4) therapy
Sufferer is selected according to the standard of Section 2, takes pharmaceutical composition of the present invention, 1 drug of control group, 2 medicine of control group
Object, it is with all worries set aside to repose, heavy physical labour or strenuous exercise are avoided, avoids and stays up late, avoids eating ternip, Hua Dou, is avoided pungent food and cold drink.
(5) treatment results
| It cures | Effectively | In vain | Total effective rate | |
| Experimental group of the present invention | 764 | 235 | 1 | 99.9% |
| Compare prescription 1 | 71 | 340 | 589 | 41.1% |
| Compare prescription 2 | 93 | 368 | 539 | 46.1% |
From the above it is found that the pharmaceutical composition of the present invention can effectively treat coronary heart disease, and it is with obvious effects due to
Prescription 1, control prescription 2 are compareed, illustrates that the cooperation of each drug of the present invention has played collaboration left and right.
To sum up, compared with the drug of existing treatment coronary heart disease, composition of the invention is more safe and effective, can be applied to be preced with
The diseases such as worry, myocardial ischemia, angina pectoris, treatment deficiency of vital energy weak, headache due to deficiency of blood, palpitation and insomnia, the obstruction of qi in the chest, before having a vast market application
Scape.
Claims (9)
1. a kind of pharmaceutical composition for preventing and/or treating coronary heart disease, it is characterised in that：It is matched containing following weight
The preparation that is prepared of bulk pharmaceutical chemicals：40~60 parts of Radix Astragali, 5~15 parts of Radix Angelicae Sinensis, 3~9 parts of Radix Glycyrrhizae, 5~15 parts of ganoderma lucidum, tealeaves 5
~15 parts, 5~15 parts of Herba Epimedii, 40~60 parts of Radix Salviae Miltiorrhizae, 5~15 parts of rose rhodobryum herb, 5~15 parts of ginseng, 1~3 part of radix aconiti agrestis.
2. pharmaceutical composition according to claim 1, it is characterised in that：It is the bulk pharmaceutical chemicals system matched containing following weight
Preparation made of standby：50 parts of Radix Astragali, 10 parts of Radix Angelicae Sinensis, 6 parts of Radix Glycyrrhizae, 10 parts of ganoderma lucidum, 10 parts of tealeaves, 10 parts of Herba Epimedii, 50 parts of Radix Salviae Miltiorrhizae,
10 parts of rose rhodobryum herb, 10 parts of ginseng, 2 parts of radix aconiti agrestis.
3. pharmaceutical composition according to claim 1 or 2, it is characterised in that：The tealeaves is green tea.
4. according to claims 1 to 3 any one of them pharmaceutical composition, it is characterised in that：It is medicinal powder by bulk pharmaceutical chemicals, original
The water or extractive with organic solvent for expecting medicine are active constituent, in addition the preparation that acceptable auxiliary material is prepared in pharmacy.
5. according to Claims 1 to 4 any one of them pharmaceutical composition, it is characterised in that：The preparation is oral preparation；It is excellent
Choosing, the oral preparation is decoction, powder, capsule, tablet, granule.
6. pharmaceutical composition according to claim 5, it is characterised in that：The oral preparation is tea bag.
7. a kind of method preparing any one of claim 1~6 described pharmaceutical composition, it is characterised in that：It includes following step
Suddenly：
1) each bulk pharmaceutical chemicals are weighed by weight ratio；
2) medicinal powder, water or extractive with organic solvent of bulk pharmaceutical chemicals are taken, in addition acceptable auxiliary material or complementary ingredient system in pharmacy
For at preparation.
8. any one of claim 1~7 composition prepare prevent and/or treatment coronary heart disease, myocardial ischemia, angina pectoris,
Treatment deficiency of vital energy weak, headache due to deficiency of blood, palpitation and insomnia and/or the obstruction of qi in the chest drug in purposes.
9. purposes according to claim 8, it is characterised in that：The drug is to alleviate ambition secret anguish, palpitation, burnout
Weak, complexionWhite and/or cyanosis of the lips and nails drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810550888.4A CN108403857A (en) | 2018-05-31 | 2018-05-31 | A kind of pharmaceutical composition and its preparation method and application for preventing and/or treating coronary heart disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810550888.4A CN108403857A (en) | 2018-05-31 | 2018-05-31 | A kind of pharmaceutical composition and its preparation method and application for preventing and/or treating coronary heart disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108403857A true CN108403857A (en) | 2018-08-17 |
Family
ID=63141062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810550888.4A Pending CN108403857A (en) | 2018-05-31 | 2018-05-31 | A kind of pharmaceutical composition and its preparation method and application for preventing and/or treating coronary heart disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108403857A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101953935A (en) * | 2009-07-13 | 2011-01-26 | 青岛国风药业股份有限公司 | Qi-nourishing and blood-activating medicinal composition and preparation method, detection method and application thereof |
| US20120063996A1 (en) * | 2000-05-18 | 2012-03-15 | Elan Pharma International Ltd. | Novel nimesulide compositions |
| CN103977142A (en) * | 2014-06-06 | 2014-08-13 | 马朝富 | Traditional Chinese medicine preparation for treating coronary heart disease and preparation method thereof |
-
2018
- 2018-05-31 CN CN201810550888.4A patent/CN108403857A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120063996A1 (en) * | 2000-05-18 | 2012-03-15 | Elan Pharma International Ltd. | Novel nimesulide compositions |
| CN101953935A (en) * | 2009-07-13 | 2011-01-26 | 青岛国风药业股份有限公司 | Qi-nourishing and blood-activating medicinal composition and preparation method, detection method and application thereof |
| CN103977142A (en) * | 2014-06-06 | 2014-08-13 | 马朝富 | Traditional Chinese medicine preparation for treating coronary heart disease and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 姚颜红: "回心草在心血管疾病中的研究进展", 《哈尔滨医药》 * |
| 王佑华: "回心草治疗冠心病30例临床疗效观察", 《中国中医药科技》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101467673A (en) | Compound ginseng health product and preparation method thereof | |
| CN103989970B (en) | A kind of Chinese medicine composition treating hypertension | |
| CN109528953A (en) | There is a kind of pair of microcirculation in human body the grass that crosses of improvement result to collect Chinese medicine plant composition | |
| CN103520655A (en) | Traditional Chinese medicine composition for treating psoriasis vulgaris and preparation method thereof | |
| CN104524481B (en) | A kind of Chinese medicine for treating IBS and preparation method thereof | |
| CN105394282A (en) | Radix puerariae health tea capable of reducing blood pressure, blood sugar and blood lipid | |
| CN102949571B (en) | Medicine for treating chronic osteomyelitis | |
| CN105012873A (en) | Health-care blood-fat-lowering evening primrose oral liquid and preparation method thereof | |
| CN108653722A (en) | A kind of Chinese medicine composition, preparation method and application | |
| CN105055967B (en) | A kind of complex health care product and preparation method with auxiliary hyperglycemic function | |
| CN104645015A (en) | Traditional Chinese medicine compound preparation for treating vascular dementia and preparation method of traditional Chinese medicine compound preparation | |
| CN103920011A (en) | Pharmaceutical composition for postpartum liver depression qi stagnation type hypogalactia and preparing method thereof | |
| CN107753602A (en) | A kind of Chinese medicine composition for treating leukaemia and preparation method thereof | |
| CN108403857A (en) | A kind of pharmaceutical composition and its preparation method and application for preventing and/or treating coronary heart disease | |
| CN106138831A (en) | A kind of Chinese medicine composition treating cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN106389892A (en) | Food therapy powder and preparation method thereof | |
| CN105106634A (en) | Traditional Chinese medicine preparation for treating acute appendicitis and application thereof | |
| CN104398626A (en) | Rheumatic heart disease merging palpitation heart and spleen-supplementing medicament and preparation method thereof | |
| CN109771567A (en) | A kind of formula of Chinese herbal medicine supporting vital QI and dispersing blood stasis toxin expelling tumour | |
| CN108543036A (en) | A kind of antitumor drug and preparation method thereof | |
| CN103961603B (en) | Traditional Chinese medicine preparationcapable of reducing blood fat and freeing vessels | |
| CN103720870B (en) | Traditional Chinese medicament preparation for treating myocarditis and preparation method thereof | |
| CN106806684A (en) | It is a kind of to treat Chinese medicine preparation of hepatitis B and preparation method thereof | |
| CN106474297A (en) | Improve pharmaceutical composition of gerontal patient's postoperative cognition disorders and preparation method thereof | |
| CN105288166A (en) | Traditional Chinese medicine composition for thyroid enlargement and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180817 |